[1]
|
Choudhury S, Ramos M, Anjum H, et al. Shrinking Lung Syndrome: A Rare Manifestation of Systemic Lupus Erythematosus[J]. Cureus, 2020, 12: e8216. |
[2]
|
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292: 344-347. doi: 10.1056/NEJM197502132920706 |
[3]
|
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups[J]. Arthritis Rheumatol, 2017, 69: 2271-2282. doi: 10.1002/art.40320 |
[4]
|
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51: 237-267. doi: 10.1016/j.jhep.2009.04.009 |
[5]
|
Albayda J, Khan A, Casciola-Rosen L, et al. Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement[J]. Semin Arthritis Rheum, 2018, 47: 552-556. doi: 10.1016/j.semarthrit.2017.06.004 |
[6]
|
Huang Y, Liu H, Wu C, et al. Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement[J]. Rheumatology (Oxford), 2021, 60: 3809-3816. doi: 10.1093/rheumatology/keaa872 |
[7]
|
Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics[J]. Science, 2014, 346: 945-949. doi: 10.1126/science.1253735 |
[8]
|
Dalakas MC. Inflammatory muscle diseases[J]. N Engl J Med, 2015, 372: 1734-47. doi: 10.1056/NEJMra1402225 |
[9]
|
Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflam-matory myopathies[J]. Lancet Neurol, 2018, 17: 816-828. doi: 10.1016/S1474-4422(18)30254-0 |
[10]
|
薄传强. 特发性炎性肌病[J]. 中华神经科杂志, 2019, 52: 410-422. doi: 10.3760/cma.j.issn.1006-7876.2019.05.009
Bu CQ. Idiopathic inflammatory myopathy[J]. Zhonghua Shenjingke Zazhi, 2019, 52: 410-421. doi: 10.3760/cma.j.issn.1006-7876.2019.05.009 |
[11]
|
Hou Y, Liu M, Luo YB, et al. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort[J]. Neuromuscul Disord, 2019, 29: 5-13. doi: 10.1016/j.nmd.2018.11.004 |
[12]
|
Mauhin W, Mariampillai K, Allenbach Y, et al. Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies[J]. Joint Bone Spine, 2018, 85: 375-376. doi: 10.1016/j.jbspin.2017.04.004 |
[13]
|
Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti- mitochondrial antibodies[J]. Brain, 2012, 135: 1767-1777. doi: 10.1093/brain/aws106 |
[14]
|
Uenaka T, Kowa H, Ohtsuka Y, et al. Less limb muscle involvement in myositis patients with anti-mitochondrial antibodies[J]. Eur Neurol, 2017, 78: 290-295. doi: 10.1159/000481503 |